Investors Research Corp’s Pfizer PFE Stock Holding History

Investors Research Corp’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$938K	Buy	38,962 +481	+1%	+$12.6K	0.17%	104
2026 Q1	$1.08M	Sell	38,481 -2,398	-6%	-$63.8K	0.21%	94
2025 Q4	$1.02M	Buy	40,879 +201	+0.5%	+$5.07K	0.19%	104
2025 Q3	$1.04M	Buy	40,678 +1	+0%	+$25	0.19%	108
2025 Q2	$986K	Buy	40,677 +1	+0%	+$23	0.19%	107
2025 Q1	$1.03M	Buy	40,676 +9,853	+32%	+$258K	0.22%	98
2024 Q4	$818K	Sell	30,823 -11,382	-27%	-$309K	0.18%	124
2024 Q3	$1.22M	Hold	42,205	–	–	0.27%	78
2024 Q2	$1.18M	Buy	42,205 +3,300	+8%	+$90.9K	0.28%	78
2024 Q1	$1.08M	Sell	38,905 -666	-2%	-$18.5K	0.25%	96
2023 Q4	$1.14M	Hold	39,571	–	–	0.28%	86
2023 Q3	$1.31M	Buy	39,571 +17,154	+77%	+$607K	0.34%	62
2023 Q2	$822K	Hold	22,417	–	–	0.21%	131
2023 Q1	$915K	Hold	22,417	–	–	0.24%	112
2022 Q4	$1.15M	Buy	22,417 +60	+0.3%	+$2.88K	0.31%	83
2022 Q3	$978K	Sell	22,357 -300	-1%	-$14.6K	0.3%	81
2022 Q2	$1.19M	Hold	22,657	–	–	0.36%	64
2022 Q1	$1.17M	Sell	22,657 -295	-1%	-$15.3K	0.33%	81
2021 Q4	$1.35M	Sell	22,952 -6	-0%	-$297	0.41%	66
2021 Q3	$987K	Buy	22,958 +643	+3%	+$28.5K	0.33%	88
2021 Q2	$874K	Buy	22,315 +3	+0%	+$117	0.3%	110
2021 Q1	$808K	Sell	22,312 -2,075	-9%	-$73.7K	0.3%	111
2020 Q4	$898K	Sell	24,387 -1,738	-7%	-$63.8K	0.35%	84
2020 Q3	$910K	Hold	26,125	–	–	0.44%	54
2020 Q2	$811K	Hold	26,125	–	–	0.41%	66
2020 Q1	$809K	Sell	26,125 -286	-1%	-$9.74K	0.5%	33
2019 Q4	$982K	Hold	26,411	–	–	0.45%	53
2019 Q3	$900K	Buy	26,411 +759	+3%	+$27.6K	0.46%	53
2019 Q2	$1.05M	Buy	25,652 +105	+0.4%	+$4.17K	0.55%	34
2019 Q1	$1.03M	Sell	25,547 -316	-1%	-$12.7K	0.55%	33
2018 Q4	$1.07M	Sell	25,863 -510	-2%	-$21.2K	0.75%	20
2018 Q3	$1.1M	Buy	26,373 +63	+0.2%	+$2.42K	0.63%	28
2018 Q2	$906K	Buy	26,310 +2,084	+9%	+$71.2K	0.53%	48
2018 Q1	$816K	Hold	24,226	–	–	0.5%	53
2017 Q4	$833K	Buy	+24,226	New	+$826K	0.52%	51

Other funds holding PFE

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

CWP

Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Welch Group Birmingham, Alabama $2.93B AUM 27.62% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

Investors Research Corp's PFE Position: Q2 2026 in Review

Investors Research Corp increased its Pfizer (PFE) stake by 1.2% in Q2 2026, buying an estimated $12.6K and bringing the position to 38,962 shares worth $938K. The position accounts for 0.17% of the portfolio, ranked #104.

Investors Research Corp first reported a position in PFE in Q4 2017 and has held it in 35 quarters since. The position peaked at $1.35M in Q4 2021. 799 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Investors Research Corp held 38,962 shares of Pfizer worth $938K as of Q2 2026.
Investors Research Corp bought 481 Pfizer shares in Q2 2026, an estimated $12.6K.
Pfizer made up 0.17% of Investors Research Corp's portfolio in Q2 2026, its #104 holding.
Investors Research Corp first reported a position in Pfizer in Q4 2017 and has held it in 35 quarters since.
Investors Research Corp's Pfizer position peaked at $1.35M in Q4 2021.
799 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Investors Research Corp's 13F filing for Q2 2026, filed 10 Jul 2026.